Soft wave therapy shows real biological effects on tissue, but the clinical picture is more nuanced than marketing materials suggest. The treatment, a form of extracorporeal shockwave therapy (ESWT), uses acoustic pressure waves to stimulate healing responses in damaged tissue. It has FDA clearance for only two specific conditions, though it’s widely marketed for a much broader range of musculoskeletal problems. Whether it “works” depends heavily on what you’re treating and what you expect.
What Soft Wave Therapy Actually Does to Tissue
The therapy delivers focused sound waves into injured or painful areas of the body. These waves trigger a cascade of cellular responses that promote healing. Specifically, the shockwaves stimulate the release of a growth factor called VEGF, which drives the formation of new blood vessels in the treated area. They also boost production of a compound called eNOS, which relaxes blood vessels and improves circulation to the site. Both responses peak around 12 weeks after treatment before gradually returning to baseline levels.
At a deeper level, the waves activate stem cell proliferation and increase markers associated with bone and tissue repair. Animal studies have shown measurable increases in cell growth, bone-building proteins, and the formation of new blood vessel networks at tendon and bone junctions after treatment. These biological effects are well documented in laboratory and animal research. The question is how consistently they translate into meaningful relief for patients.
What the FDA Has Actually Cleared It For
Despite being marketed for everything from knee arthritis to shoulder tendonitis, the FDA has cleared soft wave devices for just two indications: chronic diabetic foot ulcers (smaller than 16 square centimeters, lasting more than 30 days) and superficial partial-thickness second-degree burns. Both clearances specify use alongside standard wound care, not as a standalone treatment, and apply only to adults 22 and older.
This doesn’t mean the therapy is useless for other conditions. It means those other uses haven’t gone through the FDA’s formal review process. Many clinics use the device off-label for plantar fasciitis, tendon injuries, joint pain, and other musculoskeletal problems. Off-label use is legal and common in medicine, but it means the evidence bar is lower than what FDA clearance requires.
How Long Results Last
A meta-analysis of randomized controlled trials found that shockwave therapy reduced pain and improved joint mobility for up to 12 weeks after treatment. Patients who received ESWT showed statistically significant improvements in range of motion compared to control groups at the 12-week mark. Pain scores also improved, though the difference between treated and untreated groups narrowed over time and lost statistical significance by 12 weeks in some comparisons.
That 12-week window aligns with the biological data showing that the growth factors stimulated by shockwave therapy peak around week 12 and then decline to baseline. In practical terms, this suggests the therapy creates a temporary healing window rather than a permanent fix. Some patients may experience lasting improvement if the underlying tissue successfully repairs during that period, while others may need repeat treatments.
Focused vs. Radial Shockwaves
Not all shockwave devices are the same. Focused shockwave therapy penetrates deeper into tissue and can be adjusted to target structures at specific depths. Radial shockwave therapy has a more superficial effect, reaching roughly half the depth of focused waves. For conditions affecting deeper structures like tendons or joints, focused waves generally deliver more energy to the problem area. The “soft wave” devices marketed under that brand name use a type of focused, unfocused, or electrohydraulic technology, so it’s worth asking your provider which type of device they use and how deep the waves penetrate.
What Treatment Feels Like
A gel is applied to your skin (similar to an ultrasound), and the device is pressed against the treatment area. Most patients describe the sensation as small pulses against the skin. There can be discomfort, particularly over tender or inflamed areas, but it’s generally tolerable. Your provider can adjust the intensity if the pain becomes significant. No anesthesia or numbing is typically required.
A standard course involves three to five sessions spaced about one week apart. Some providers recommend up to 12 sessions depending on the condition being treated.
Side Effects and Safety Risks
The most common side effects are skin redness, mild bruising, and soreness at the treatment site. Less common complications include blood pooling under the skin, nerve irritation, swelling, and a theoretical risk of tendon rupture. These risks are generally considered low for the energy levels used in most clinical settings.
The International Society for Medical Shockwave Treatment lists specific contraindications. You should not receive low-energy shockwave therapy over a cancerous tumor or a fetus. High-energy focused waves carry additional restrictions: they should not be applied over lung tissue, the brain or spine, growth plates in bones, or in patients with severe blood-clotting disorders.
Cost and Insurance Coverage
Soft wave therapy is not covered by Medicare, Medicaid, or private insurance. You’ll pay entirely out of pocket. A typical treatment plan of six to twelve sessions runs between $900 and $2,400, with individual sessions costing $150 to $250 each. Some clinics offer a discounted first session so you can gauge your response before committing to a full course.
Given the lack of insurance coverage and the limited FDA clearances, you’re essentially paying for a treatment where the biological mechanisms are sound but the clinical evidence for many common uses remains incomplete. The therapy is unlikely to cause harm for most people, but it’s worth having realistic expectations: measurable benefits when they occur tend to peak around 12 weeks, and not every patient responds. If you’re considering it for a specific condition, ask your provider what evidence supports its use for that particular problem, not just for shockwave therapy in general.